Dr. Reddy's messages are multiplied by eight

The company was selling a generic product in the US market prior to the granting of a temporary prohibition order

Dr. Reddy & # 39; s Laboratories recorded a jump of eight times its consolidated net profit, recording Rs 456.1 crore against Rs 59.1 crore, aided by operational efficiency, forex gains and the launch of gSuboxone, the generic version of an opioid addiction drug on the US market in the first quarter

consolidated business figure at Rs 3.720.7 crore against Rs 3,315.9 crore in the same quarter last year . Earnings before interest, taxes, depreciation and amortization (EBITDA) for the quarter were Rs 807.1 million, an increase of 140% year-over-year (year-on-year).

"The focus on operational efficiency has helped improve margin profile.In the future, although we continue to experience price erosion in the generic market in America, North, we will continue to drive growth and costs while improving our quality management systems and building healthy portfolios in the markets we serve. "

Emphasis will be on generic construction complex, biosimilars and differentiated products, he adds.

"Some of the gross margin improvement is attributed to the gSuboxone, but benefited from foreign exchange gains and gains in operational efficiency." Forex gain also contributed to the 400- 500 basis points to profit, "said Saumen Chakraborty, president and global director of human resources, Dr. Reddy's.

The company was selling generic products in the US market before the grant of an order Temporary Restriction (ORT) As a reminder, the New Jersey District Court granted a preliminary injunction against Dr. Reddy's on the sale of a generic version of the prescription drug. Indivior, gSuboxone, in the US The court prevented Dr. Reddy from relaunching his generic product until the patent litigation was concluded or until it was over. 39; overrides an appeal from this injunction.

Emerging market revenues, which account for 18% of generic sales, declined. 21% to Rs 664.3 crore. However, Russia's revenues increased by 9% to 380 crore due to new launches and volume traction in some of the key molecules.